http://thefly.com/landingPageNews.php?id=3100142&headline=LPCN-Lipocine-price-target-raised-to-from-at-HC-Wainwright "H.C. Wainwright analyst Oren Livnat raised the firm's price target on Lipocine to $3 from $2 and keeps a Buy rating on the shares. The analyst revived the prospects of Tlando, an oral testosterone replacement therapy, after recent developments." TLANDO has been assigned a PDUFA date of August 28 by the FDA. Lipocine has another drug, LPCN 1144, currently in a Phase 2 trial for NASH and expects top-line results in H2.